Integra LifeSciences (IART) Cash Flow Statement

Click line-items for a historical chart and %

Net income	46.32M
Depreciation and amortization	54.35M
In-process research and development
Deferred income tax provision (benefit)	-2.92M
Share-based compensation	12.77M
Amortization of debt issuance costs	1.62M
Non-cash interest expense
Payment of accreted interest	0
Gain on convertible note repurchases
Excess tax benefits from stock-based compensation arrangements
Other, net
Accounts receivable	-8.1M
Inventories	-9.06M
Prepaid expenses and other current assets	1.05M
Refundable income taxes
Other non-current assets	-552K
Accounts payable, accrued expenses and other current liabilities	5.83M
Deferred revenue	1.38M
Other liabilities
Net cash provided by operating activities	109.88M
Cash used in business acquisitions, net of cash acquired	0
Purchases of property and equipment	-26.14M
Purchases of intangible assets
Net cash used in investing activities	-21.48M
Borrowings under senior credit facility	15M
Repayments under senior credit facility	-48.75M
Repurchase of liability component of convertible notes	0
Debt issuance costs	0
Purchases of treasury stock
Proceeds from exercised stock options	9.93M
Excess tax benefits from stock-based compensation arrangements	-4.57M
Net cash (used in) provided by financing activities	-28.88M
Effect of exchange rate changes on cash and cash equivalents	-51K
Net increase (decrease) in cash and cash equivalents	59.47M
Cash and cash equivalents at beginning of period	48.13M
Cash and cash equivalents at end of period	107.6M

Entities mentioned with IART

View All Entities